1. Home/
  2. Compounds/
  3. alisertib:navitoclax (2:1 mol/mol)

alisertib:navitoclax (2:1 mol/mol)


SourcesNames Used
CTRPv2alisertib:navitoclax (2:1 mol/mol)
PharmacoGx alisertib:navitoclax (2:1 mol/mol)

Cell lines tested with alisertib:navitoclax (2:1 mol/mol)

775 cell lines have been tested with this compound, using data from 1 dataset(s).
A549 lung CTRPv23
DU-145 prostate CTRPv22
AsPC-1 pancreas CTRPv22
NCI-H1869 lung CTRPv22
CCF-STTG1 central nervous system CTRPv22
OAW-28 ovary CTRPv22
HeLa cervix CTRPv22
LOXIMVI haematopoietic and lymphoid tissue CTRPv22
NCI-H520 lung CTRPv22
MKN74 stomach CTRPv22
Download CSV

Tissues tested with alisertib:navitoclax (2:1 mol/mol)

25 tissues have been tested with this compound, using data from 1 dataset(s).
haematopoietic and lymphoid tissueCTRPv2121
large intestineCTRPv244
central nervous systemCTRPv243
Download CSV
Download Data as CSV

Top molecular features associated with response to alisertib:navitoclax (2:1 mol/mol)

Feature TypeStandardized
Nominal ANOVA
mRNA ZBED4 CTRPv2 AAC 0.28 2e-12
mRNA ADNP2 CTRPv2 AAC 0.23 4e-11
mRNA RCC2 CTRPv2 AAC 0.26 9e-11
mRNA ZNF766 CTRPv2 AAC 0.24 1e-10
mRNA WRN CTRPv2 AAC 0.24 2e-10
mRNA LDOC1L CTRPv2 AAC 0.24 2e-10
mRNA KLHL23 CTRPv2 AAC 0.24 3e-10
mRNA KCNH3 CTRPv2 AAC 0.22 5e-10
mRNA CBX2 CTRPv2 AAC 0.24 6e-10
mRNA ZNF407 CTRPv2 AAC 0.23 9e-10
Download CSV